Democratizing access
to Precision Oncology
while improving
patients' lives.

Democratizing access to Precision Oncology while improving patients' lives.

+ Learn more
Precision Oncology

Shifting away from
the one-size-fits-all
approach

Shifting away from the one-size-fits-all approach.

Historically, cancer treatment has relied on a one-size-fits-all approach where drugs and other therapies designed to target large groups of individuals are prescribed based on population parameters, but not on the individual patient’s likelihood of positive response. Precision oncology is here to change that.

Historically, cancer treatment has relied on a one-size-fits-all approach where drugs and other therapies designed to target large groups of individuals are prescribed based on population parameters, but not on the individual patient’s likelihood of positive response. Precision oncology is here to change that.

Our Platform

Providing valuable
insights through
our Drug Activity
Ranking

Providing valuable insights through our Drug Activity Ranking

We're developing a proprietary Drug Activity Ranking to provide oncologists with actionable patient-derived data to aid them in the therapy selection process.

Platform
Capabilites

We're leveraging deep scientific expertise in screening technologies combined with the power of high-throughput flow cytometry to better understand how patients may respond to drugs, before they're actually prescribed.

The Team

You're in good
company

OncoPrecision's Team is driven by a strong conviction and belief that each person is unique and therefore requires tailored care.

Gastón has a degree in Genetics and a PhD in Cell Biology from Instituto Leloir and the University of Buenos Aires, including a research internship at the Erasmus Medical Center in the Netherlands. He returned to Argentina in 2012 after conducting his postdoctoral training at the Institut Curie in Paris. Together, these experiences account for 13 years of training in different aspects of cancer research, with focus on DNA replication, DNA repair and epigenetics.

In 2013, Gastón took a position as Assistant Professor & Researcher in the National University of Córdoba and in 2014 he formed his own team for translational cancer research. His group aims to develop phenotypic screening platforms to identify novel targets and drugs for cancer therapy that work through the principle of synthetic lethality. In the past 5 years, his group has established important research agreements with pharmaceutical companies such as GlaxoSmithKline, which led to fundraising, joint publications and bidirectional MTAs and technology licensing. In 2020, a part of Gastón’s group moved to FPM, a high-complexity diagnostics Lab, to start a project on precision oncology through the development of screening assays using patient-derived cancer cells, which lay the foundations for OncoPrecision.

Gastón Soria, PhD

Co-Founder & CSO

Candelaria graduated with a degree in Biology from the Physics and Natural Sciences College of the National University of Córdoba in 2009. Between the years 2012 and 2017, Candelaria was enrolled in a PhD program at the National University of Córdoba, where she focused on the cellular and molecular biology of cancer. The key areas of research for her PhD were mechanisms for intervention in tumoral progression, metastasis and antitumoral therapy resistance.

While enrolled in the PhD program, Candelaria conducted field work at Dr. Kazanietz’s laboratory at the Pharmacology Department of the University of Pennsylvania in 2015. She also spent several months during 2017 and 2018 working at Dr. Gutkind’s laboratory at the Moores Cancer Center of University of California, San Diego. During these work experiences, Candelaria received grants from distinguished institutions such as the Journal of Cell Science, the International Union of Biochemistry and Molecular Biology, and Fullbright – Bunge & Born.

Candelaria Llorens, PhD

Co-Founder & Director of Lab Operations

Gerardo has a degree in Biochemistry and a PhD in Immunology from the College of Chemical Science of the National University of Córdoba. His postdoctoral training took place at the Fundación para el Progreso de la Medicina (FPM), a high-complexity diagnostics lab in Córdoba, Argentina. Gerardo conducted field work at Dr. Mandruzzato’s laboratory at the Department of Oncological and Surgical Sciences, at the University of Padova, Italy and Dr. Coussens’ laboratory at the Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University in Portland.

He has extensive research experience in the fields of immunology and immuno-oncology. In 2013, he led a team of researchers that conducted clinical evaluations of new biomarkers in solid tumors, one of the objectives of the Translational exploration consortium in clinical oncology (FPM, CONICET and Clinic Hospital consortium). In 2014, Gerardo took a position as researcher at FPM where he leads his own immunology cancer research team. His group has conducted important research on new prognosis biomarkers discovery and therapeutic targets in breast cancer.

Gerardo Gatti, PhD

Co-Founder & Medical-Scientific Liaison

Tarek studied Entrepreneurship at Babson College in Wellesley, Massachusetts. While at Babson, he co-founded Ando, an urban last-mile package delivery platform based in Buenos Aires that was later acquired by Moova, a well-funded startup in the same space. After graduating Summa Cum Laude from Babson in 2018, Tarek joined a private equity firm in New York called Gatewood Capital Partners, driven to better understand the dynamics of mergers and acquisitions, with the goal of being prepared for future opportunities.

He was an Analyst for the firm’s US$220 million debut fund for a year. He later returned to Argentina in August 2019 and joined Moova to continue to build on the Ando legacy, but with the conviction of eventually starting a new venture to bring about positive change in the field of oncology.

Tarek A. Zaki

Co-Founder & CEO

Our Partners

Resources

Selected Papers

Identification of PLK1 as a therapeutic target in BRCA1-deficient cancers (2019)

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

Bioprospecting South American flora for synthetic lethal lead compounds (2020)

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

Screening of regulatory partners of ZEB1 to inhibit its pro-metastatic properties (2019)

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

Repurposing of breast cancer transcriptomic signature for pan-cancer applications (2020)

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.

Identification of PLK1 as a therapeutic target in BRCA1-deficient cancers (2019)

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

Bioprospecting South American flora for synthetic lethal lead compounds (2020)

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

Screening of regulatory partners of ZEB1 to inhibit its pro-metastatic properties (2019)

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

Repurposing of breast cancer transcriptomic signature for pan-cancer applications (2020)

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.